The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (June 2021).
| Autor: | Hanson, Kimberly E, Altayar, Osama, Caliendo, Angela M, Arias, Cesar A, Englund, Janet A, Hayden, Mary K, Lee, Mark J, Loeb, Mark, Patel, Robin, Alayli, Abdallah El, Sultan, Shahnaz, Falck-Ytter, Yngve, Lavergne, Valery, Mansour, Razan, Morgan, Rebecca L, Murad, M Hassan, Patel, Payal, Bhimraj, Adarsh, Mustafa, Reem A |
|---|---|
| Předmět: |
RNA analysis
MEDICAL protocols COMMUNICABLE diseases MEDICAL information storage & retrieval systems STATISTICAL models RESEARCH funding COVID-19 testing REVERSE transcriptase polymerase chain reaction DISEASE prevalence DESCRIPTIVE statistics COVID-19 vaccines VIRAL antigens SYSTEMATIC reviews MEDLINE MEDICAL databases UNIVERSAL healthcare ONLINE information services DATA analysis software CONFIDENCE intervals COVID-19 NUCLEIC acid amplification techniques MOLECULAR diagnosis SENSITIVITY & specificity (Statistics) VACCINATION status IMMUNOCOMPETENCE |
| Zdroj: | Clinical Infectious Diseases; Jun2024, Vol. 78 Issue 7, pe208-e229, 22p |
| Abstrakt: | Immunoassays designed to detect SARS-CoV-2 protein antigens are now commercially available. The most widely used tests are rapid lateral flow assays that generate results in ~15 minutes for diagnosis at the point-of-care. Higher throughput, laboratory-based SARS-CoV-2 antigen (Ag) assays have also been developed. The overall accuracy of SARS-CoV-2 Ag tests, however, is not well defined. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the literature and develop best-practice guidance related to SARS-CoV-2 Ag testing. This guideline is the third in a series of rapid, frequently updated COVID-19 diagnostic guidelines developed by IDSA. IDSA's goal was to develop evidence-based recommendations or suggestions that assist clinicians, clinical laboratories, patients, public health authorities, administrators, and policymakers in decisions related to the optimal use of SARS-CoV-2 Ag tests in both medical and nonmedical settings. A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review identified and prioritized clinical questions related to the use of SARS-CoV-2 Ag tests. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. The panel agreed on 5 diagnostic recommendations. These recommendations address Ag testing in symptomatic and asymptomatic individuals as well as assess single versus repeat testing strategies. Data on the clinical performance of US Food and Drug Administration SARS-CoV-2 Ag tests with Emergency Use Authorization are mostly limited to single, one-time testing versus standard nucleic acid amplification testing (NAAT) as the reference standard. Rapid Ag tests have high specificity and low to modest sensitivity compared with reference NAAT methods. Antigen test sensitivity is heavily dependent on viral load, with differences observed between symptomatic compared with asymptomatic individuals and the time of testing post-onset of symptoms. Based on these observations, rapid reverse transcriptase–polymerase chain reaction (RT-PCR) or laboratory-based NAAT remain the diagnostic methods of choice for diagnosing SARS-CoV-2 infection. However, when molecular testing is not readily available or is logistically infeasible, Ag testing can help identify some individuals with SARS-CoV-2 infection. The overall quality of available evidence supporting use of Ag testing was graded as very low to moderate. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|